Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS)
CNY9.09
+0.19 (+2.13%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Building 1 200040
Shanghai, CN
Shanghai, CN
CEO
Yong Liu
Website
shyndec.com
IPO
2004-06-16
ISIN CNE000001JG2
Description
Shanghai Shyndec Pharmaceutical Co., Ltd., established in 1996 and headquartered in Shanghai, China, operates as a pharmaceutical enterprise. The company focuses on the global production of various drug formulations. Its primary therapeutic areas of specialization include anti-infectives, cardiovascular and cerebrovascular treatments, oncology, metabolic disorders, and endocrine system conditions.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY9.09
+0.19 (+2.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.12
Float Shares
695.76M
Free Float %
51.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10% | -1.64% | -10.79% | -9.78% | -7.97% | -5.05% | -6.98% | -30.91% | -12.50% | -33.63% | +365.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9.09
DCF (Unlevered)
30.23
+232.5%
DCF (Levered)
35.08
+285.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.89
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-14.4% Q1'26: -20.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-13.6% Q1'26: -63.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.4% Q1'26: +24.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.2% ★ Q1'26: +12.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+7.3% ★ Q1'26: +6.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.57× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.99B
est: 3.20B (+181.1%)
|
9.13B
est: 5.92B (+54.2%)
|
8.52B
est: 3.20B (+166.4%)
|
11.32B
est: 5.92B (+91.3%)
|
12.20B
est: 10.22B (+19.4%)
|
12.56B
est: 11.35B (+10.6%)
|
13.94B
est: 12.97B (+7.6%)
|
12.96B
est: 14.14B (-8.3%)
|
10.94B
est: 11.83B (-7.5%)
|
9.36B
est: 11.28B (-17.0%)
|
9.00B
9.00B – 9.00B
-20.1% YoY
|
9.15B
9.15B – 9.15B
+1.6% YoY
|
9.50B
9.50B – 9.50B
+3.8% YoY
|
| EBITDA |
1.84B
est: 488.69M (+276.7%)
|
2.07B
est: 904.69M (+128.4%)
|
2.03B
est: 488.69M (+315.3%)
|
2.24B
est: 904.69M (+147.3%)
|
1.99B
est: 1.56B (+27.7%)
|
1.90B
est: 1.73B (+9.6%)
|
1.81B
est: 1.98B (-8.8%)
|
1.93B
est: 2.16B (-10.9%)
|
2.46B
est: 2.10B (+17.1%)
|
2.08B
est: 2.01B (+3.7%)
|
1.60B
1.60B – 1.60B
-20.1% YoY
|
1.63B
1.63B – 1.63B
+1.6% YoY
|
1.69B
1.69B – 1.69B
+3.8% YoY
|
| EBIT |
1.15B
est: 287.71M (+299.7%)
|
1.34B
est: 532.62M (+151.9%)
|
1.22B
est: 287.71M (+322.5%)
|
1.51B
est: 532.62M (+182.7%)
|
1.27B
est: 919.80M (+38.3%)
|
1.17B
est: 1.02B (+15.0%)
|
1.03B
est: 1.17B (-11.8%)
|
1.10B
est: 1.27B (-13.9%)
|
1.71B
est: 1.31B (+30.9%)
|
1.33B
est: 1.25B (+6.6%)
|
995.26M
995.26M – 995.26M
-20.1% YoY
|
1.01B
1.01B – 1.01B
+1.6% YoY
|
1.05B
1.05B – 1.05B
+3.8% YoY
|
| Net Income |
529.99M
est: 543.17M (-2.4%)
|
476.93M
est: 523.06M (-8.8%)
|
515.80M
est: 543.17M (-5.0%)
|
705.52M
est: 523.06M (+34.9%)
|
656.37M
est: 992.47M (-33.9%)
|
648.79M
est: 898.59M (-27.8%)
|
568.28M
est: 1.03B (-45.0%)
|
627.79M
est: 1.14B (-44.9%)
|
1.08B
est: 1.19B (-9.2%)
|
944.38M
est: 1.19B (-20.9%)
|
844.99M
844.99M – 844.99M
-29.2% YoY
|
925.47M
925.47M – 925.47M
+9.5% YoY
|
1.02B
1.02B – 1.02B
+10.1% YoY
|
| SGA |
1.71B
est: 831.20M (+105.3%)
|
1.89B
est: 1.54B (+23.1%)
|
2.09B
est: 831.20M (+151.0%)
|
3.90B
est: 1.54B (+153.7%)
|
4.23B
est: 2.66B (+59.3%)
|
4.02B
est: 2.95B (+36.2%)
|
4.20B
est: 3.37B (+24.6%)
|
3.41B
est: 3.68B (-7.2%)
|
1.92B
est: 2.32B (-17.3%)
|
—
est: 2.21B (-100.0%)
|
1.76B
1.76B – 1.76B
-20.1% YoY
|
1.79B
1.79B – 1.79B
+1.6% YoY
|
1.86B
1.86B – 1.86B
+3.8% YoY
|
| EPS |
0.56
est: 0.41 (+38.3%)
|
0.43
est: 0.39 (+10.3%)
|
0.46
est: 0.41 (+13.6%)
|
0.65
est: 0.39 (+66.7%)
|
0.62
est: 0.74 (-16.2%)
|
0.63
est: 0.67 (-6.0%)
|
0.55
est: 0.77 (-28.6%)
|
0.61
est: 0.85 (-28.2%)
|
0.81
est: 0.89 (-9.0%)
|
0.70
est: 0.89 (-21.3%)
|
0.63
0.63 – 0.63
-29.2% YoY
|
0.69
0.69 – 0.69
+9.5% YoY
|
0.76
0.76 – 0.76
+10.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
477.52M
OE per share TTM
0.36
Owner's Yield
3.71%
Maintenance CapEx ratio
9.73%
Maint CapEx / Avg PPE
44.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 23.5K | 0.44% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 454.5K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 156.7K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 15.6K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 35.2K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.74M | 0.06% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 81.4K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 100.5K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 24.2K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.76M | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
115.8K
Shares Outstanding
1.34B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lei Gao | Accounting Supervisor | — | — |
| Xiangchen Wang | Chief Financial Officer | — | male |
| Yong Liu | President & Director | — | male |
| Zhongxi Zhang | Vice President & Board Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600420.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
